|
Basiliximab
Product Approval Information - Licensing Action
Proper name: Basiliximab
Tradename: Simulect
Manufacturer: Novartis Pharmaceutical Corp, East Hanover, NJ, License #1244
Indication for Use: Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids
Approval Date: 5/12/98
Type of submission: Biologics license application
Approval Letter
(PDF),
(Text)
SBA memo (PDF)
Label (PDF)
Reviews (PDF)
Chemistry, Manufacturing and Controls (20 pages)
Clinical Efficacy and Safety (36 pages)
Clinical Pharmacology (17 pages)
Product (30 pages)
Pharmacology (3 pages)
Statistical (17 pages)
Last Updated: 3/5/2001
 Back
to Top 
Back to Index
Date created: September 16, 2003 |
